Using modeling to inform international guidelines for antiretroviral treatment

AIDS

Volumn 28, Issue SUPPL. 1, 2014, Pages

  Hallett, Timothy B ^a   Menzies, Nicolas A ^b   Revill, Paul ^c   Keebler, Daniel ^d,e   Bórquez, Annick ^a   McRobie, Ellen ^a   Eaton, Jeffrey W ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF YORK   (United Kingdom)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE POLICY; HEPATITIS B; HEPATITIS C; HIV TEST; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORBIDITY; MORTALITY; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEXUAL BEHAVIOR; VERTICAL TRANSMISSION; VIRUS LOAD;

ANTI-RETROVIRAL AGENTS; HEALTH POLICY; HIV INFECTIONS; HUMANS; MODELS, STATISTICAL; PRACTICE GUIDELINES AS TOPIC; WORLD HEALTH;

EID: 84893284705     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000115     Document Type: Article

References (19)

1. The World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2013. http://www.who.int/hiv/pub/guidelines/arv2013/en/(accessed 31 July 2013).
2. Garnett GP, Cousens S, Hallett TB, Steketee R, Walker N. Mathematical models in the evaluation of health programmes. Lancet 2011; 378:515-525.
3. Eaton JW, Johnson LF, Salomon JA, Barnighausen T, Bendavid E, Bershteyn A, et al. HIV treatment as prevention: Systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med 2012; 9:e1001245.
4. The HIV Modelling Consortium Treatment as Prevention Editorial Writing Group. HIV treatment as prevention: Models, data, and questions: Towards evidence-based decision-making. PLoS Med 2012; 9:e1001259.
5. Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, et al. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: A combined analysis of 12 mathematical models. Lancet Glob Health 2014; 2:e23-e34.
6. Keebler D, Revill P, Braithwaite S, Phillips A, Blaser N, Bórquez A, et al. Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: A combined analysis of three mathematical models. Lancet Glob Health 2014; 2:e35-e43.
7. Gopalappa C, Stover J, Shaffer N, Mahy M. The costs and benefits of Option BR for the prevention of mother-to-child transmission of HIV. AIDS 2013; 27:S251-S260.
8. Cambiano V, Bertagnolio S, Jordan MR, Pillay D, Perriens JH, Venter F, et al. Predicted levels of HIV drug resistance in South Africa: Potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral therapy initiation. AIDS 2013; 27:S261-S269.
9. Pretorius C, Menzies NA, Chindelevitch L, Cohen T, Cori A, Eaton JW, et al. The potential effects of changing HIV treatment policy on tuberculosis outcomes in South Africa: Results from three tuberculosis-HIV transmission models. AIDS 2013; 27:S271-S280.
10. Martin NK, Devine A, Eaton JW, Miners A, Hallett TB, Foster GR, et al. Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South Africa. AIDS 2013; 27:S281-S292.
11. Klein DJ, Bershteyn A, Eckhoff PA. Dropout and re-enrollment: Implications for epidemiological projections of treatment programs. AIDS 2013; 27:S293-S305.
12. Mishra S, Mountain E, Pickles M, Vickerman P, Shastri S, Gilks C, et al. Exploring the population-level impact of antiretroviral treatment: The influence of baseline intervention context. AIDS 2013; 27:S307-S318.
13. Braithwaite RS, Nucifora KA, Toohey C, Kessler J, Uhler LM, Mentor SM, et al. How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa AIDS 2013; 27:S319-S329.
14. Easterbrook PH, Doherty MC, Perriens JH, Barcarolo JL, Hirnschall GO. The role of mathematical modelling in the development of recommendations in the 2013 WHO consolidated antiretroviral therapy guidelines. AIDS 2013; 27:S331-S338.
15. Hallett TB, Eaton JW. A side-door into care cascade for HIV-infected patients J Acquir Immune Defic Syndr 2013; 63 (Suppl 2):S228-S232.
16. Keeling MJ, Rohani P. Modeling infectious diseases in humans and animals. Princeton, NJ: Princeton University Press; 2007.
17. Delva W, Wilson DP, Abu-Raddad L, Gorgens M, Wilson D, Hallett TB, et al. HIV treatment as prevention: Principles of good HIV epidemiology modelling for public health decisionmaking in all modes of prevention and evaluation. PLoS Med 2012; 9:e1001239.
18. Edejer TT-T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans D, Murray CJL. Making Choices in Health: WHO guide to costeffectiveness analysis (p. 318). Geneva: World Health Organisation; 2003, 1-329.
19. Revill P, Sculpher M. Cost effectiveness of interventions to tackle noncommunicable diseases. BMJ 2012; 344:e609.